PDCD1 and non-small cell lung carcinoma: Moreover, both sets suggested that the high scores cohort had a higher probability of favorable efficacy to anti-PD-1 therapy than low score cohort (NSCLC set 77.78 vs. 22.22%, P = 0.002; other tumors set 87.50 vs. 25.00%, P = 0.006; Figure 6D).